FENC trades 54.3% below Wall Street's consensus target of $17.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes FENC achieves its forward estimates and maintains a stable P/E multiple of 44.4x. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Fennec Pharmaceuticals Inc. (FENC) has a Wall Street consensus price target of $17.00, based on estimates from 7 covering analysts. With the stock currently trading at $11.02, this represents a potential upside of +54.3%. The company has a market capitalization of $315M.
Analyst price targets range from a low of $16.00 to a high of $18.00, representing a 12% spread in expectations. The median target of $17.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, FENC trades at a trailing P/E of -30.6x and forward P/E of 44.4x. Analysts expect EPS to grow +205.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
LCTXLineage Cell Therapeutics, Inc. | $319M | $1.28 | — | — | Buy | — | 5 |
SNOASonoma Pharmaceuticals, Inc. | $2M | $1.12 | — | — | — | — | — |
HALOHalozyme Therapeutics, Inc. | $8.9B | $74.96 | $88.25 | +17.7% | Buy | 9.2x | 27 |
SUPNSupernus Pharmaceuticals, Inc. | $2.7B | $46.84 | $65.00 | +38.8% | Buy | 18.8x | 14 |
PTCTPTC Therapeutics, Inc. | $7.0B | $84.43 | $95.83 | +13.5% | Buy | 95.3x | 26 |
RCKTRocket Pharmaceuticals, Inc. | $355M | $3.25 | $5.00 | +53.8% | Buy | — | 19 |
RAREUltragenyx Pharmaceutical Inc. | $3.0B | $30.77 | $48.36 | +57.2% | Buy | — | 33 |
JAZZJazz Pharmaceuticals plc | $14.4B | $230.02 | $257.44 | +11.9% | Buy | 9.1x | 48 |
PRGOPerrigo Company plc | $1.4B | $9.95 | $36.20 | +263.8% | Hold | 4.7x | 36 |
PAHCPhibro Animal Health Corporation | $1.3B | $31.69 | $49.00 | +54.6% | Buy | 10.3x | 14 |
Quick answers to the most common questions about buying FENC stock.
The consensus Wall Street price target for FENC is $17, representing 54.3% upside from the current price of $11.02. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
FENC has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $17 implies 54.3% upside from current levels.
At a forward P/E of 44.3818x, FENC trades at a premium valuation. The consensus price target of $17 (54.3% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $18 for FENC, while the most conservative target is $16. The consensus of $17 represents the median expectation. These targets typically reflect 12-month expectations.
FENC is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month FENC stock forecast based on 7 Wall Street analysts shows a consensus price target of $17, with estimates ranging from $16 (bear case) to $18 (bull case). The median consensus rating is "Buy".
FENC trades at a forward P/E ratio of 44.4x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on FENC, with a "Buy" consensus rating and $17 price target (54.3% upside). 7 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
FENC analyst price targets range from $16 to $18, a 12% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $17 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.